ArticleJournal of molecular histology2026
METTL14 mitigates osteoporosis progression by promoting osteogenic differentiation of BMMSCs through improving mitochondrial dysfunction.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Osteoporosis, a prevalent metabolic bone disorder characterized by diminished bone mass and microarchitectural deterioration, poses a significant global health burden. Bone marrow mesenchymal stem cells (BMMSCs) are crucial for bone homeostasis, and their declined osteogenic potential is a key pathogenic factor in osteoporosis. This study investigates the role of METTL14 in BMMSCs, hypothesizing that it attenuates osteoporosis progression by enhancing their osteogenic differentiation. Osteogenic and adipogenic differentiation were assessed by Alizarin Red and Oil Red O staining, respectively. Cell proliferation was evaluated using the CCK-8 assay, and protein expression was analyzed by Western blot. An ovariectomized (OVX) rat model of osteoporosis was established, with bone changes examined through histopathology and immunohistochemistry. Mitochondrial function was assessed via JC-1 staining, ROS/ATP assays, and respiratory chain protein expression analysis. METTL14 upregulation enhanced BMMSC proliferation, promoted osteogenic differentiation, and increased osteogenesis-related protein expression, whereas its suppression had opposing effects. In OVX rats, METTL14 elevation improved bone repair and improved mitochondrial function by recovering membrane potential, reducing mitochondrial ROS, increasing ATP production, and normalizing respiratory chain protein expression. METTL14 mitigates osteoporosis progression by promoting osteogenic differentiation of BMMSCs through improving mitochondrial dysfunction. Our research provides a foundation for targeting METTL14 in osteoporosis treatment.
Indexed as
Identifiers
41843018What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.